Search

Introduction: Statins are a class of lipid lowering medication which can effectively lower cardiovascular mortality and morbidity by the beneficial effects in atherosclerotic cardiovascular disease. Recently, there are increasing concerns over the relationship between statins and cognitive deficits. On the contrary, some studies have indicated an improvement in memory functions with the use of statins. However, the impact of statins on cognition is still unclear. Aim: To analyse the effect of statins on cognition and memory using Mini-Mental Scale Examination (MMSE). Materials and Methods: The case control study was conducted in Department of Cardiology at PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India (tertiary care teaching hospital), from June 2019 to December 2019. Out of total 127 participants, case group included 63 adult patients of both gender, on statin therapy for at least 12 weeks duration and control group included 64 age and gender matched adults who were not on statin therapy. After obtaining a written informed consent, MMSE questionnaire was administered by a trained blinded interviewer to both groups. Pearson's correlation was done to evaluate anysignificant correlation between duration of statin therapy with MMSE and individual domain scores. Data was analysed using Statistical Package for Social Sciences (SPSS) version 24.0, and p-value <0.05 was considered significant. Results: The mean age of the cases was 61.1±7.90 years, and that of the control group was 60.6±7.68 years. Using the cut-off score of 23 to diagnose dementia, 21 (33.3%) cases and 24 (37.5%) control participants had cognitive deficits, with no statistically significant difference. The mean score of patients on statin therapy for more than one year (26.45±3.03) was higher compared to those with less than or equal to one year duration of therapy (24.48±4.11), but did not reach statistical significance. But, statistically significant difference between mean scores of cases and controls was evident in cognitive domains like registration (p-value=0.01) and recall (p-value=0.04) in addition to a significant correlation (p-value=0.03) between the duration of statin therapy and orientation score. Conclusion: This study refutes the possibility of an association of statin therapy with cognitive decline in the study population. On the other hand, the results are illustrative of a potential cognitive benefit with the use of statins. [ABSTRACT FROM AUTHOR]

Aims: This pilot study sought to determine whether the Malayalam adaptation of Addenbrooke’s Cognitive Examination (M-ACE) can effectively identify patients with amnestic mild cognitive impairment (a-MCI) and the impact of measures of learning and free recall. Materials and Methods: A cohort of 23 patients with a-MCI aged between 55-80 years diagnosed as per current criteria and 23 group matched cognitively normal healthy controls (CNHC) were studied. The measures of acquisition and delayed recall were the Rey Auditory Verbal Learning Test (RAVLT) and Wechsler Memory Scale (WMS)-III (verbal and visual subsets) and Delayed Matching-to-sample Test (DMS)-48. Test scores of M-ACE registration and recall scores were included. To examine the differences in test performances between the groups, we compared the number of subjects with test scores less than 1.5 standard deviation (SD) of the control scores. Comparisons between a-MCI and controls were drawn using Fisher's exact test and Mann-Whitney U tests. Results: M-ACE registration component ascertained on a 24-point scale failed to demonstrate any differences between a-MCI and controls (P = 0.665) as opposed to recall judged on a cumulative 10-point scale (P = 0.001). Significant differences were noted in RAVLT list learning (P < 0.001) and list recall (P = 0.003), WMS-III paragraph learning (P <0.001) and recall (P = 0.007), visual learning (P = 0.004) and recall (P = 0.001). Conclusions: M-ACE recall scores are an effective screening tool to identify patients with suspected a-MCI. Both word list and paragraph learning and recall components have been found to be sensitive to concretely identify a-MCI and impairment on at least 2 tests should be considered in the diagnostic criteria of MCI rather than rely on a single screening battery. [ABSTRACT FROM AUTHOR]